146 related articles for article (PubMed ID: 18451529)
1. Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure.
Horiuchi I; Nozawa T; Fujii N; Inoue H; Honda M; Shimizu T; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2008 May; 31(5):976-80. PubMed ID: 18451529
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure.
Saito M; Kawana J; Ohno T; Hanada K; Kaneko M; Mihara K; Shiomi M; Nagayama M; Sumiyoshi T; Ogata H
Biol Pharm Bull; 2010; 33(8):1378-84. PubMed ID: 20686235
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis.
Takekuma Y; Takenaka T; Kiyokawa M; Yamazaki K; Okamoto H; Kitabatake A; Tsutsui H; Sugawara M
Biol Pharm Bull; 2007 Mar; 30(3):537-42. PubMed ID: 17329852
[TBL] [Abstract][Full Text] [Related]
4. UGT2B7*3 did not affect the pharmacokinetics of R- and S-carvedilol in healthy Japanese.
Honda M; Toyoda W; Shimizu T; Horiuchi I; Kayano Y; Taguchi M; Nozawa T; Inoue H; Hashimoto Y
Drug Metab Pharmacokinet; 2007 Oct; 22(5):382-6. PubMed ID: 17965522
[TBL] [Abstract][Full Text] [Related]
5. Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients.
Graff DW; Williamson KM; Pieper JA; Carson SW; Adams KF; Cascio WE; Patterson JH
J Clin Pharmacol; 2001 Jan; 41(1):97-106. PubMed ID: 11225566
[TBL] [Abstract][Full Text] [Related]
6. Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers.
Honda M; Ogura Y; Toyoda W; Taguchi M; Nozawa T; Inoue H; Hashimoto Y
Biol Pharm Bull; 2006 Apr; 29(4):772-8. PubMed ID: 16595916
[TBL] [Abstract][Full Text] [Related]
7. Effect of CYP2D6*10 on the pharmacokinetics of R- and S-carvedilol in healthy Japanese volunteers.
Honda M; Nozawa T; Igarashi N; Inoue H; Arakawa R; Ogura Y; Okabe H; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2005 Aug; 28(8):1476-9. PubMed ID: 16079496
[TBL] [Abstract][Full Text] [Related]
8. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency.
Gehr TW; Tenero DM; Boyle DA; Qian Y; Sica DA; Shusterman NH
Eur J Clin Pharmacol; 1999 Jun; 55(4):269-77. PubMed ID: 10424319
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
Packer M; Lukas MA; Tenero DM; Baidoo CA; Greenberg BH;
Am J Cardiol; 2006 Oct; 98(7A):39L-45L. PubMed ID: 17023231
[TBL] [Abstract][Full Text] [Related]
10. Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol.
Fukumoto K; Kobayashi T; Komamura K; Kamakura S; Kitakaze M; Ueno K
Drug Metab Pharmacokinet; 2005 Dec; 20(6):423-7. PubMed ID: 16415527
[TBL] [Abstract][Full Text] [Related]
11. Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism.
Nardotto GHB; Coelho EB; Paiva CE; Lanchote VL
J Clin Pharmacol; 2017 Jun; 57(6):760-769. PubMed ID: 28114735
[TBL] [Abstract][Full Text] [Related]
12. [Structure and activity of carvedilol].
Zarudyĭ FS; Garifullin BN; Zakirova AN
Eksp Klin Farmakol; 2010 Jan; 73(1):40-3. PubMed ID: 20184288
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients.
Nardotto GHB; Lanchote VL; Coelho EB; Della Pasqua O
Eur J Pharm Sci; 2017 Nov; 109S():S108-S115. PubMed ID: 28522373
[TBL] [Abstract][Full Text] [Related]
14. Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure.
Tenero D; Boike S; Boyle D; Ilson B; Fesniak HF; Brozena S; Jorkasky D
J Clin Pharmacol; 2000 Aug; 40(8):844-53. PubMed ID: 10934668
[TBL] [Abstract][Full Text] [Related]
15. Exercise does not affect plasma concentrations of (R)- and (S)-carvedilol.
Stoschitzky K; Koshucharova G; Zweiker R; Lercher P; Maier R; Klein W; Zitta S; Gruber L; Lamprecht G; Lindner W
Cardiovasc Drugs Ther; 2002 Mar; 16(2):133-40. PubMed ID: 12090906
[TBL] [Abstract][Full Text] [Related]
16. Chiral analysis of carvedilol and its metabolites hydroxyphenyl carvedilol and O-desmethyl carvedilol in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical pharmacokinetic study.
Nardotto GHB; Coelho EB; Marques MP; Lanchote VL
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Mar; 1015-1016():173-180. PubMed ID: 26927877
[TBL] [Abstract][Full Text] [Related]
17. Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol.
Takekuma Y; Takenaka T; Kiyokawa M; Yamazaki K; Okamoto H; Kitabatake A; Tsutsui H; Sugawara M
J Pharm Pharm Sci; 2006; 9(1):101-12. PubMed ID: 16849011
[TBL] [Abstract][Full Text] [Related]
18. Carvedilol: a countermeasure to heart failure.
Barkman A; Pooler C
Dimens Crit Care Nurs; 2001; 20(5):11-6. PubMed ID: 22076514
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
[TBL] [Abstract][Full Text] [Related]
20. Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity.
Takekuma Y; Takenaka T; Yamazaki K; Ueno K; Sugawara M
Biol Pharm Bull; 2007 Nov; 30(11):2146-53. PubMed ID: 17978490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
